Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.
Our Fool likes the look of these stock market juggernauts for the chunky passive income they throw off, not to mention their ...
The latest research suggests that the recombinant shingles vaccine may offer additional benefits. It appears to reduce the ...
Data from a late-stage study shows that co-administering GSK's RSV and Shingles vaccines together was as effective as giving ...
If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...
UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...
GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix.
GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the ...
GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales
In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...
GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...
GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older.
The trial testing the immune response of co-administration of GSK's blockbuster vaccines, Shingrix and Arexvy, in adults over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback